Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the envision open label extension
Year: 2020
Type: article
Source: Journal of Hepatology
Authors: Eliane Sardh, Manisha Balwani, David Rees, Penelope Stein, Ulrich Stözel, Paula Aguilera, D. Montgomery Bissell, Herbert Bonkovsky, Sioban Keel, Charles Parket, John Phillips, Samuel Silver, Jerzy Windyga, Delia D’Avola, Gayle Ross, Peter Stewart, Bruce Ritchie, Pauline Harper, Jiaan-Der Wang, Janneke Langendonk Langendonk, Aneta Ivanova, Yutaka Horie, Karl Anderson, Paolo Ventura, Maria Domenica Cappellini, Daphne Vassiliou, Susana Monroy-Santoyo, Petro Petrides, Tomohide Adachi, David Kuter, Sushama Scalera, Craig Penz, Gary Liu, John Ko, Amy Simon, Laurent Gouya
Institutions: Karolinska University Hospital, University Hospital Carl Gustav Carus, Technische Universität Dresden, The Royal Free Hospital, University College London, Icahn School of Medicine at Mount Sinai, King's College Hospital NHS Foundation Trust, King's College Hospital, Klinikum Chemnitz, Universitat de Barcelona, University of California, San Francisco, Atrium Health Wake Forest Baptist, Wake Forest University, University of Washington, University of Utah, University of Michigan, Instytut Hematologii i Transfuzjologi, The Royal Melbourne Hospital, Melbourne Health, Royal Prince Alfred Hospital, University of Alberta, Taichung Veterans General Hospital, University Hospital St. Ivan Rilski, Tottori University, The University of Texas Medical Branch at Galveston, University of Modena and Reggio Emilia, University of Milan, Instituto Nacional de Pediatria, Saiseikai Central Hospital, Massachusetts General Hospital, Alnylam Pharmaceuticals (United States), Hospital Clínic de Barcelona, Hôpital Louis-Mourier
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4238024163